Du är här

2016-02-18

Novartis International AG: Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.

Novartis International AG / Alcon expands leadership position in treating
glaucoma through acquisition ofTranscend Medical, Inc. . Processed and
transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
* Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to
pipeline, expanding Alcon's surgical presence in a new category to treat
glaucoma
* The goal of MIGS is to reduce or eliminate the need for glaucoma
medications
* More than 60 million people worldwide are affected by glaucoma which may
lead to progressive vision loss[1,2]

Basel, Switzerland, February 18, 2016 -
Alcon, the global leader in eye care and a division of Novartis, announced
today that it has entered into an agreement to acquire Transcend Medical,
Inc., a privately-held, US-based company focused on developing
minimally-invasive surgical devices to treat glaucoma.

Transcend Medical, Inc. has recently developed a micro-stent to treat mild to
moderate glaucoma. The MIGS device is implanted just below the surface of the
eye. It is designed to treat less severe glaucoma by enhancing part of the
natural drainage pathways of the eye with minimal tissue disruption. This
allows the excess fluid in the eye to drain with the goal of reducing
intraocular pressure (IOP) levels.

"We expect the MIGS technology to be a great addition to our device pipeline
and to establish Alcon's presence in this new surgical category to treat
glaucoma," said Mike Ball, CEO of Alcon. "If approved, it will provide a less
invasive means of lowering IOP than traditional invasive glaucoma surgery,
with the goal of lowering the dependency of topical ocular medication. This
acquisition also expands Alcon's leadership in glaucoma and cataract
treatment as part of our Surgical business."

More than 60 million people globally are affected by glaucoma. Elevated IOP,
generally associated with glaucoma, may lead to progressive damage of the
optic nerve and vision loss. A patient's IOP can be managed with eye drops,
oral medications, laser surgery, traditional invasive surgery or a
combination of these methods.

A study with over 500 patients with mild-to-moderate glaucoma undergoing
cataract surgery randomized to either receive the MIGS Micro-Stent after
cataract surgery or undergo no further intervention met its primary and
secondary endpoints in 2015 resulting in a 20% or greater reduction in IOP.
Transcend Medical, Inc. currently has CE Mark approval for the micro-stent in
Europe and is awaiting US Food and Drug Administration approval of the
device. Financial terms of the acquisition were not disclosed.

About Glaucoma

More than 60 million people globally are affected by glaucoma that can lead to
progressive damage of the optic nerve. Early diagnosis of glaucoma is
critical to managing the disease, as it is often asymptomatic and therefore
can go undetected until it is at an advanced stage. As the disease advances,
patients may experience loss of peripheral (side) vision, tunnel vision or
eye spots. Glaucoma can eventually result in gradual, irreversible loss of
vision and blindness. The exact cause of glaucoma is unknown. However,
elevated pressure in the eye (intraocular pressure, or IOP) is generally
present with glaucoma and is the only known modifiable risk factor. As a
chronic disease, patients can be treated with eye drops, oral medications,
laser surgery, traditional surgery or a combination of these methods.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by words such as "to add," "pipeline," "goal," "may," "designed,"
"expect," "will," or similar terms, or by express or implied discussions
regarding potential completion of the announced acquisition of Transcend
Medical, Inc., or regarding potential future marketing approvals for the
micro-stent or the other pipeline projects discussed in this release, or
regarding potential future revenues from the micro-stent, such other pipeline
projects, or the acquisition of Transcend Medical, Inc. You should not place
undue reliance on these statements. Such forward-looking statements are based
on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that the proposed acquisition will be completed in
the expected form or within the expected time frame or at all. Nor can there
be any guarantee that Novartis will be able to realize any of the potential
strategic benefits, synergies or opportunities as a result of the
acquisition. Neither can there be any guarantee that the micro-stent or the
other pipeline projects discussed in this release will be submitted or
approved for sale in any additional markets, or at any particular time. Nor
can there be any guarantee that the acquisition of Transcend Medical, Inc.,
will achieve any or all of its intended goals and objectives, or be
commercially successful. Nor can there be any guarantee that the micro-stent
or the portfolio of pipeline projects and marketed products discussed in this
release will be commercially successful in the future. In particular,
management's expectations regarding the micro-stent, the other pipeline
projects and marketed products discussed in this release, and the acquisition
of Transcend Medical, Inc., could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally,
including an unexpected failure to obtain necessary government approvals for
the transactions, or unexpected delays in obtaining such approvals; the
potential that any other closing conditions for any of the transactions might
not be met; the potential that the strategic benefits, synergies or
opportunities expected from the transactions may not be realized or may take
longer to realize than expected; the uncertainties inherent in research and
development, including unexpected clinical trial results and additional
analysis of existing clinical data; the company's ability to obtain or
maintain proprietary intellectual property protection; general economic and
industry conditions; global trends toward health care cost containment,
including ongoing pricing pressures; unexpected safety issues; unexpected
manufacturing or quality issues, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2015, the Group
achieved net sales of USD 49.4 billion, while R&D throughout the Group
amounted to approximately USD 8.9 billion (USD 8.7 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 119,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

References

[1] Lighthouse International.Prevalence of Vision Impairment
.http://www.lighthouse.org/research/statistics-on-vision-impairment/preva....

[2] Quigley and Broman.The Number of People with Glaucoma Worldwide in 2010
and 2020
. Br J Ophthalmol 2006;90:262-7.

# # #

Novartis Media Relations

----------------------------------------------------------------
| Central media line : |
|+41 61 324 2200 |
| Eric Althoff Elizabeth R. Harness |
| |
|Novartis Global Media Relations Novartis Alcon Communications |
|+41 61 324 7999 (direct) + 1 817 551 8696 (direct) |
|+41 79 593 4202 (mobile) + 1 585 435 7379 (mobile) |
|eric.althoff@novartis.com elizabeth.harness@alcon.com |
----------------------------------------------------------------
e-mail:media.relations@novartis.com

Novartis Investor Relations

----------------------------------------------------------------------------------
| Central phone: +41 61 324 7944 North America: |
| Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448 |
| Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417 |
| Thomas Hungerbuehler +41 61 324 8425 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
----------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/1987120/729261.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#1987120

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.